Abstract
The purpose of this case series review is to describe our 12 month clinical experience with intra-articular injections of Botulinum toxin Type A (BoNT/A) for refractory joint pain. Eleven patients with chronic arthritis who had failed treatment with oral and/or intra-articular medications and were not surgical candidates were referred to us for management of moderate to severe refractory joint pain in 15 joints. The use of BoNT/A to treat joint pain is a non-FDA approved “off label” treatment with potential side effects. After a detailed explanation of the joint injection procedure, signed informed consent was obtained for the procedure. Fifteen joints were injected with BoNT/A (Allergan, Inc): six lower extremity joints (3 knees, 3 ankles) with 25-50 units and nine shoulders with 50-100 units. Patients were followed for one year or longer. Maximum relief of pain was measured by comparing baseline pain on a numeric rating scale (0-10) to pain at the time of maximum relief (paired t-test). Maximum improvement in function was assessed using paired t-tests for improvement in active flexion and abduction for the shoulder joint, and by the time to perform sit to stand ten times (the timed stands test, TST) for the lower extremity joints.
Results: Two patients were female and nine were male, aged 42-82 years. Five had osteoarthritis (OA), five had rheumatoid arthritis (RA) and one had psoriatic arthritis. All patients were on analgesic and/or anti-inflammatory medications and all joints had previous intra-articular steroid or viscosupplement injections with inadequate or unsatisfactory benefit. A clinically and statistically significant improvement was noted after IA-BoNT/ A injections. The mean maximum decrease in lower extremity joint pain was 55% (p =0.02) and the 36% (p =0.044) improvement in the Timed Stands Test was noted at four to ten weeks after injection. There was a 71% mean maximum reduction in shoulder pain severity from 8.2 ± 1.1 to 2.4 ± 1.9 (p <0.001). Active range of motion increased 67% in flexion (from 67.8 ± 27.6 to 113.3 ± 46.6 degrees, p =0.001) and 42% in abduction (from 50 18.5 degrees to 71.1 ± 23.1 degrees p =0.01). No immediate or delayed adverse effects related to BoNT/A were noted after the injection. Duration of pain relief was variable and ranged from 3 to 12 months. Five joints were re-injected with IA-BoNT/A and had a similar decrease in joint pain that lasted 3 to 12 months. Conclusions: This is the first report of the long term effects of intra-articular BoNT/A injections to treat chronic joint pain and the efficacy of repeated injections. Although this study was small, and uncontrolled the results suggest that IA-BoNT/ A injections are an effective and safe treatment for chronic joint pain disorders.
Similar content being viewed by others
References
Adebajo AO, P Nash and BL Hazleman (1990) A prospective double blind dummy placebo controlled study comparing tri-amcinolone hexacetonide injection with oral diclofenac 50 mg TDS in patients with rotator cuff tendinitis.J. Rheumatol. 17(9), 1207–1210.
Alper BS and PR Lewis (2002) Review: tricyclic antidepressants, capsaicin, gabapentin, and oxycodone are effective for posther-petic neuralgia.J. Fam. Pract. 51, 121–128.
American College of Rheumatology (2000) Recommendations for the medical management of osteoarthritis of the hip and knee, 2000 Update. ACR Subcommittee on Osteoarthritis Guidelines.Arth. Rheum. 43, 1905–1915.
American Pain Society (2002)Guideline for the Management of Pain in Osteoarthritis, Rheumatoid Arthritis, and Juvenile Chronic Arthritis, 2nd Edition (American Pain Society: Glenview, IL), pp 1–184.
Aoki KR (2003) Evidence for antinociceptive activity of botulinum toxin type A in pain management.Headache 43 Suppl. 1, S9-S15.
Arezzo J (2002) Possible mechanisms for the effects of Botulinum toxin on pain.Clin. J. Pain 18 (Suppl), S125-S132.
Bergenudd H, F Lindgarde, B Nilsson and CJ Petersson (1988) Shoulder pain in middle age. A study of prevalence and relation to occupational work load and psychosocial factors.Clin. Orthop. 231, 234–238.
Berry H, L Fernandes, B Bloom, RJ Clark and EB Hamilton (1980) Clinical study comparing acupuncture, physiotherapy, injection and oral anti-inflammatory therapy in shoulder-cuff lesions.Curr. Med. Res. Opin. 7(2), 121–126.
Binder A, G Parr, B Hazleman and S Fitton-Jackson (1984) Pulsed electromagnetic field therapy of persistent rotator cuff tendinitis. A double-blind controlled assessment.Lancet 1(8379), 695–698.
Bjelle A (1989) Ageing and disorders of the locomotor system.Scand. J. Rheumatol. Suppl.82, 3–12. Review.
Blomqvist P, N Feltelius, A Ekbom and L Klareskog (2000) Rheumatoid arthritis in Sweden. Drug prescriptions, costs, and adverse drug reactions.J. Rheumatology 27(5), 1171–1177.
Brashear A, M Gordon, E Elovic, V Kassicieh, M Do, C Lee, S Jenkins and C Turkel (2002) Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke.N. Engl. J. Med. 347, 395–400.
Brin M (1997) Botulinum toxin: chenistry, pharmacology, toxiciy, and immunology.Muscle Nerve 6 (Suppl.), S146-S168.
Brin MF, S Fahn, C Moskowitz, A Friedman, H M Shale, PE Greene, A Blitzer, T List, D Lange, RE Lovelaceet al. (1987) Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm.Mov. Disord. 2(4), 237–254.
Brin MF, S Fahn, C Moskowitz, A Friedman, HM Shale, PE Greene, A Blitzer, T List, D Lange, RE Lovelaceet al. (1988) Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm.Adv. Neurol. 50, 599–608.
Brin MF, MF Lew, CH Adler, CL Comella, SA Factor, J Jankovic, C O’Brien, JJ Murray, JD Wallace, A Willmer-Hulme and M Koller (1999) Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia.Neurology 53(7), 1431–1438.
Chakravarty KK and M Webley (1990) Disorders of the shoulder: an often unrecognised cause of disability in elderly people.Bmj 300(6728), 848–849.
Chard MD, BL Hazleman and MD Devereux (1988) Controlled trial to investigate dose-response patterns to portable pulsed electromagnetic fields in the treatment of rotator cuff tendinitis.J. Orthop. Rheumatol. 1, 33–40.
Chard MD, R Hazleman, BL Hazleman, RH King and BB Reiss (1991) Shoulder disorders in the elderly: a community survey.Arthritis Rheum. 34(6), 766–769.
Clements P and P. He (1997)Nonsteroidal Antirheumatic Drugs. Textbook of Rheumatology (Kelley W, S Ruddy, E Harris and C Sledge, Eds.) (WB Saunders: Philadelphia, PA)1, 707–740.
Comella CL, J Jankovic and MF Brin (2000) Use of botulinum toxin type A in the treatment of cervical dystonia.Neurology 55 (Suppl. 5), S15-S21.
Cui M, Z Li, S You, S Khanijou and K Aoki (2002) Mechanisms of the antinociceptive effect of subcutaneous Botox: inhibition of peripheral and central nociceptive processing.Arch. Pharmacol. 365 (Suppl. 2), R17.
Cui M, S Khanijou, J Rubino and R Aoki (2004) Subcutaneous administration of botulinum toxin A reduces formalin-induced pain.Pain 107, 125–133.
Dionne RA and J Witter (2003) NIH-FDA Analgesic Drug Development Workshop: translating scientific advances into improved pain relief.Clin. J. Pain 19(3), 139–147.
Dolly O (2003) Synaptic transmission: inhibition of neurotrans-mitter release by botulinum toxins.Headache 43 (Suppl. 1), S16-S24.
Dolly JO, AC Ashton, C McInnes, JD Wadsworth, B Poulain, L Tauc, CC Shone and J Melling (1990) Clues to the multi-phasic inhibitory action of botulinum neurotoxins on release of transmitters.J. Physiol. (Paris) 84(3), 237–246.
Durham P (2003) Mechanism of botulinum toxin type-A inhibition of calcitonin gene-related peptide (CGRP) secretion from trigeminal nerve cells.Intl. Headache Soc., Rome, Italy.
Dykstra D and A Sidi (1990) Treatment of detrusor-sphincter dys-snergia with botulinum A toxin: a double blind study.Arch. Phys. Med. Rehabil. 71, 24–26.
Dykstra D, J. Pryor and G Goldish (1993) Use of botulinum toxin type B for the treatment of detrussor hyperreflexia in a patient with multiple sclerosis.Arch. Phys. Med. Rehabil. 84, 1399–1400.
Dykstra DD, M Stucky, S Schimpff, ML Mahowald and JA Singh (2005) Effects of intra-articular botulinum toxin type A for sacroiliac, cervical/lumbar facet and costosternal joint pain and C-2 root and lumbar disc pain. 5th Intl. Conf. onBasic and Therapeutic Aspectss of Botulinum and Tetanus Toxins, Denver, CO, USA..
Ettinger W, M Davis, J Neurhaus and K Mallon (1994) Long-term physical functioning in persons with knee osteoarthritis from NHANESI: effects of comorbid medical conditions.J. Clin. Epidemiol. 47, 809–815.
Fagien S (1999) Botox for the treatment of dynamic and hyperki-netic facial lines and furrows: adjunctive use in facial aesthetic surgery.Plast. Reconstr. Surg. 103, 701–713.
Farrar JT, RK Portenoy, JA Berlin, JL Kinman and BL Strom (2000) Defining the clinically important difference in pain outcome measures.Pain 88(3), 287–294.
Farrar JT, JP Young, L LaMoreaux, JL Werth and RM Poole (2001) Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.Pain 94, 149–158.
First ER (2000) Application of botulinum toxin to the management of neurogenic inflammatory disorders. 4921757,5670484, 5674205,5677274,5714468. US, FIRST, ERIC R. 000923884, 1-7.
Gartsman GM (1993) The shoulder: common clinical problems.Semin. Perioper. Nurs. 2(2), 75–81.
Gobel H, A Heinze, K Heinze-Kuhn and W Jost (2001) Evidence based medicine: botulinum toxin A in migraine and tension type headache.J. Neurol. 248 (Suppl.), 34–38.
Green S, R Buchbinder, R Glazier and A Forbes (2003a) Interventions for shoulder pain.Cochrane Database Syst. Rev. (1).
Green S, R Buchbinder and S Hetrick (2003b) Physiotherapy interventions for shoulder pain.Cochrane Database Syst. Rev. (2), CD004258.
Hallet M (1999) One man’s poison — clinical applications of botulinum toxin.N. Engl. J. Med. 341, 118–120.
Hay EM, E Thomas, SM Paterson, K Dziedzic and PR Croft (2003) A pragmatic randomised controlled trial of local corticosteroid injection and physiotherapy for the treatment of new episodes of unilateral shoulder pain in primary care.Ann. Rheum. Dis. 62(5), 394–399.
Hochberg M (2003) Multidisciplinary integrative approach to treating knee pain in patients with osteoarthritis.Ann. Int. Med. 139, 781–783.
Jankovic J and K Schwartz (1990) Botulinum toxin injections for cervical dystonia.Neurology 40, 277–280.
Keizer S, H Rutten, P Pilot, H Morre, J v Os and A Verburg (2002) Botulinum toxin injection versus surgical treatment for tennis elbow: a randomized pilot study.Clin. Orthop. 401, 125–131.
Lang AM (2002) Botulinum toxin therapy for myofascial pain disorders.Curr. Pain Headache Rep. 6(5), 355–360.
Lang AM (2003) Botulinum toxin type A therapy in chronic pain disorders.Arch. Phys. Med. Rehabil. 84 (Suppl. 1), S69-S73; quiz S74-S75.
Mahowald M (2000) The role of nonprescription analgesics in treating mild to moderate pain. Clinical and economic considerations.Minneapolis, Health Learning Systems.
Mahowald M (2004)Chronic Pain Management. Kelley’s Textbook of Rheumatology (Ruddy S, E Harris, C Sledge, R Budd and J Sergent, Eds.) (WB Saunders: Philadelphia, PA).
Mahowald M (2005) Opioid use by patients in an orthopedics spine clinic.Arth. Rheum. 52, 312–321.
Mahowald M, J Singh and P Majeski (2005) Opioid use for chronic spine pain.Arthritis Rheum. 52(1), 312–321.
Matsen FA 3rd, KL Smith, SE DeBartolo and G Von Oesen (1997) A comparison of patients with late-stage rheumatoid arthritis and osteoarthritis of the shoulder using self-assessed shoulder function and health status.Arthritis Care Res. 10(1), 43–47.
McAlindon T, C Cooper, J Kirwan, P Dieppe (1992) Knee pain and disability in the community.Br. J. Rheumatol. 23, 189–192.
Mena HR, PL Lomen, and LF Turner, KR Lamborn and EL Brinn (1986) Treatment of acute shoulder syndrome with flurbiprofen.Am. J. Med. 80(3A), 141–144.
Miller H (1993). Plan and Operation of the Health and Nutrition Examination Survey: United States, 1971–1973. Vital and Health Statistics Series 1. No. 10, Public Health Service, US Department of Health Service.
Montecucco C and G Schiavo (1994) Mechanism of action of tetanus and botulinum neurotoxins.Mol. Microbiol. 13(1), 1–8.
Montecucco C, G Schiavo and O Rossetto (1996) The mechanism of action of tetanus and botulinum neurotoxins.Arch. Toxicol. Suppl.18, 342–354.
Moseley J, K O’Malley, N Petersen, T Menke, B Brody, D Kuykendall, J Hollingsworth, C Ashton, N Wray (2002) A controlled trial of arthroscopic surgery for osteoarthritis of the knee.N. Engl. J. Med. 347, 81–88.
Newcomer K, H Krug and ML Mahowald (1993) Validity and reliability of the timed-stands test for patients with rheumatoid arthritis and other chronic diseases.J. Rheumatol. 20, 21–27.
Petri M, R Dobrow, R Neiman, Q Whiting-O’Keefe and WE Seaman (1987) Randomized, double-blind, placebo-controlled study of the treatment of the painful shoulder.Arthritis Rheum. 30(9), 1040–1045.
Porta M (2000) A comparative trial of botulinum toxin thye A and methylprednisolone for the treatment of myofascial pain syndrome and pain from chronic muscle spasm.Pain 85, 101–105.
Purkiss JR, MJ Welch, S Doward and KA Foster (1997) Capsaicin stimulates release of substance P from dorsal root ganglion neurons via two distinct mechanisms.Biochem. Soc. Trans. 25(3), 542S.
Purkiss J, M Welch, S Doward and K Foster (2000) Capsicin stimulated release of substance P from cultured dorsal root ganglion neurons: involvement of two distinct mechanisms.Biochem. Pharmacol. 59, 1403–1406.
Reeves B (1975) The natural history of the frozen shoulder syndrome.Scand. J. Rheumatol. 4(4), 193–196.
Relja M (2002) Pain responsiveness in cervical dystonia: different doses of botulinum toxin type A.Eur. J. Neurol. 9 (Suppl. 12), 188–189.
Richardson AT (1975) Ernest Fletcher Lecture. The painful shoulder.Proc. R. Soc. Med. 68(11), 731–736.
Rizk TE, RS Pinals and AS Talaiver (1991) Corticosteroid injections in adhesive capsulitis: investigation of their value and site.Arch. Phys. Med. Rehabil. 72(1), 20–22.
Rowland L (2002) Stroke, spasticity and botulinum toxin.N. Engl. J. Med. 347, 382–383.
Schantz EJ and EA Johnson (1992) Properties and use of botulinum toxin and other microbial neurotoxins in medicine.Microbiol. Rev. 56(1), 80–99.
Schiavo G, O Rossetto, A Santucci, BR DasGupta and C Montecucco (1992) Botulinum neurotoxins are zinc proteins.J. Biol. Chem. 267(33), 23479–23483.
Schiavo G, A Santucci, BR Dasgupta, PP Mehta, J Jontes, F Benfenati, MC Wilson and C Montecucco (1993) Botulinum neurotoxins sero-types A and E cleave SNAP-25 at distinct COOH-terminal peptide bonds.FEBSLett. 335(1), 99–103.
Scott A (1981) Botulinum toxin injection of eye muscles to correct strabismus.Trans. Am. Ophthamol. Soc. 79, 734–770.
Shaffer B, JE Tibone and RK Kerlan (1992) Frozen shoulder. A long-term follow-up.J. Bone Joint Surg. Am. 74(5), 738–746.
Simpson L (1981) The origin, structure, and pharmacological activity of botulinum toxin.Pharmacol. Rev. 33, 155–188.
Singh J, ML Mahowald and DD Dykstra (2004) Report on intra-articular botulinum toxin type A for refractory joint pain.J. Pain 5(3) Suppl. 1, S60.
Thornhill T (1997).Shoulder Pain. Textbook of Rheumatology (Kelley S, E Ruddy, E Harris and C Sledge, Eds.) (WB Saunders: Philadelphia, PA), 413–438.
Turk DC, TE Ruddy and BA Sorkin (1993) Neglected topics in chronic pain treatment outcome studies: determination of success.Pain 53(1), 3–16.
van der Heijden GJ, DA van der Windt, J Kleijnen, B W Koes and L M Bouter (1996) Steroid injections for shoulder disorders: a systematic review of randomized clinical trials.Br. J. Gen. Pract. 46(406), 309–316.
van der Heijden G, D Van der Windt, A de Winter (1997) Physiotherapy for soft tissue shoulder disorders: a systematic review of randomised clinical trials.Bmj 315, 25–30.
van der Windt DA, BW Koes, BA de Jong and LM Bouter (1995a) Shoulder disorders in general practice: incidence, patient characteristics, and management.Ann. Rheum. Dis. 54(12), 959–964.
van der Windt DA, GJ van der Heijden, RJ Scholten, BW Koes and LM Bouter (1995b) The efficacy of non-steroidal anti-inflammatory drugs (NSAIDS) for shoulder complaints. A systematic review.J. Clin. Epidemiol. 48(5), 691–704.
van der Windt DA, BW Koes, W Deville, AJ Boeke, BA de Jong and LM Bouter (1998) Effectiveness of corticosteroid injections versus physiotherapy for treatment of painful stiff shoulder in primary care: randomised trial.Bmj 317(7168), 1292–1296.
Vecchio PC, BL Hazleman and RH King (1993) A double-blind trial comparing subacromial methylprednisolone and lignocaine in acute rotator cuff tendinitis.Br. J. Rheumatol. 32(8), 743–745.
Vecchio PC, RT Kavanagh, BL Hazleman and RH King (1995) Community survey of shoulder disorders in the elderly to assess the natural history and effects of treatment.Ann. Rheum. Dis. 54(2), 152–154.
Welch MJ, JR Purkiss and KA Foster (2000) Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins.Toxicon 38(2), 245–258.
Wheeler A (1998) Botulinum toxin A, adjunctive therapy for refractory headaches associated with pericranial muscle tension.Headache 38, 468–471.
Wheeler A, P Goolkasian and S Gretz (1998) A randomized, double blind, prospecive pilot study of botulinum toxin injection for refractory, unilateral, cervicothoracic, paraspinal, myofascial pain syndrome.Spine 23, 1662–1666.
White RH, DM Paull and KW Fleming (1986) Rotator cuff tendinitis: comparison of subacromial injection of a long acting corticosteroid versus oral indomethacin therapy.J. Rheumatol. 13(3), 608–613.
Winters JC, W Jorritsma, KH Groenier, JS Sobel, B Meyboom-de Jong and HJ Arendzen (1999) Treatment of shoulder complaints in general practice: long term results of a randomised, single blind study comparing physiotherapy, manipulation, and corticosteroid injection.Bmj 318(7195), 1395–1396.
Withrington RH, FL Girgis and MH Seifert (1985) A placebo-controlled trial of steroid injections in the treatment of supraspinatus tendonitis.Scand. J. Rheumatol. 14(1), 76–78.
Ytterberg SR, ML Mahowald and SR Woods (1998) Codeine and oxy-codone use in patients with chronic rheumatic disease pain.Arthritis Rheum. 41(9), 1603–1612.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mahowald, M.L., Singh, J.A. & Dykstra, D. Long term effects of intra-articular botulinum toxin a for refractory joint pain. neurotox res 9, 179–188 (2006). https://doi.org/10.1007/BF03033937
Received:
Revised:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03033937